Skip to main content
. 2022 Sep;11(9):1796–1808. doi: 10.21037/tlcr-22-211

Table 3. Existing literature on the topic of tumoral pre-treatment PD-L1 as a biomarker for PFS.

Author, region, year EGFR+ patients PD-L1 antibody PD-L1 levels PFS Definition of progression OS
Soo (23), Seoul, 2017 70 with available PD-L1 SP142 Continuous H-score Shorter PFS for higher H-scores (P=0.017) NS No association between higher PD-L1 scores and OS (P=0.795)
Shorter PFS for 10% highest PD-L1 H-scores (P<0.001)
Su (24), Guangdong, 2018 84 with available PD-L1 SP142 TPS of strong (TC ≥50% or IC ≥10%), weak (TC 5–49% or IC 5–9%) or negative (TC and IC <5%) Shorter PFS for strong expression vs. weak/negative (P<0.001) NS Not included
Yoon (25), Seoul & Busan, 2020 131 22C3 TPS of <1%, 1–49% or ≥50% Shorter PFS for >50% vs. <1% (P=0.002) RECIST 1.1 TPS ≥50% not associated with OS (P=0.181)
Shorter PFS for >50% vs. 1–49% (P=0.002)
Yoneshima (31), Fukuoka, 2018 71, but pooled with 8 ALK+ 22C3 TPS of <1%, 1–49% or ≥50% Shorter PFS for PD-L1 >1% vs. to <1% (P=0.016) NS Not included
No significant difference in PFS between when comparing all three groups (P value not listed)
Kim (27), Seoul, 2020 66 SP263 + 22C3 + SP142 Positive/negative. Cut-off: ≥1% of viable tumor cells exhibited membrane staining No significant difference in PFS for positive vs. negative (P=0.529) NS No difference in OS (P=0.150)
Tang (28), Guangzhou, 2015 99 EIL3N Positive/negative. Cut-off: H-score of ≥5 No significant difference in PFS positive vs. negative (P=0.990) NS No difference (P=0.932)
Lin (22), Fuzhou, 2015 56 Ab58810 Positive/negative. Cut-off: mean H-score of all patients Longer PFS for positive vs. negative (P=0.001) NS, RECIST 1.1 for ORR/DCR Longer OS for positive patient (P=0.004)
Yang (26), Zhongzheng, 2020 153 22C3 TPS of <1%, 1–49% or ≥50% Shorter PFS for ≥50% vs. 0% (P=0.009) RECIST 1.1 No difference (P=0.605)
Shorter PFS for ≥50% vs. 1–49% (P=0.044)
Shorter PFS for ≥50% vs. 0–49% (P=0.007)
D’incecco (17), Italy (not further specified), 2015 54 Ab58810 Positive/negative. Cut-off: staining intensity of 2 in more than 5% of tumor cells Longer time to progression for positive vs. negative (P=0.01) NS No difference (P=0.75)
Matsumoto (32), Osaka, 2019 52 28-8 High (≥50%) or low (0–49%) Shorter PFS for high PD-L1 vs. low (P=0.0059) RECIST 1.1 Not included
Kobayashi (33), Tokyo, 2018 32 Unclear Positive/negative. Cut-off: staining intensity of 3 in more than 5% of cells No significant difference in PFS for positive vs. negative (P=0.58) NS No difference
Chang (34), New Taipei & Yilan County & Yanchao District, 2021 114 22C3 TPS of <1%, 1–49% or ≥50% No significant difference in PFS between groups (P=0.738) RECIST 1.1 No difference (P=0.769)
Kang (35), Seoul, 2021 108 22C3, SP263 TPS of <1%, 1–49% or ≥50% Significantly shorter PFS for strong vs. negative (P=0.001) RECIST 1.1 Not included
Inomata (36), 2022, Toyama 49 22C3 Positive/negative. Cut-off: TPS of 1% Significant impact of PD-L1 on time on treatment in adjusted analysis (P=0.022) RECIST 1.1 or clinical judgment Not included

Correlation with OS for included studies is also listed, as well as antibodies, cut-off values and definition of progression for each study. PD-L1, programmed death ligand-1; PFS, progression free survival; OS, overall survival; TPS, tumor proportion score; TC, tumor cells; IC, immune cells; NS, not specified.